CRL vs GH vs FTRE Stock Comparison

Charles River Laboratories International, Guardant Health and Fortrea Holdings Prices as of Nov 13, 2026 Peers: Industry group
GH Guardant Health, Inc.
$151.70 -6.9% 1M +61.2% 1Y
Market cap
$19.50B
P/E
–
Revenue (TTM)
$1.28B
Div. yield
–
Diagnostic Labs Healthcare
3 wins
FTRE Fortrea Holdings Inc.
$20.20 -5.3% 1M +97.7% 1Y
Market cap
$1.89B
P/E
–
Revenue (TTM)
$2.67B
Div. yield
–
Contract Research Healthcare
3 wins

Head to Head

10 decided of 12

Charles River Laboratories International leads on 4 of the 12 questions below (Charles River Laboratories International 4, Guardant Health 3, Fortrea Holdings 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCRLGHFTRELeader
Larger companyMarket capitalisation $16.01B $19.50B $1.89B GH
Cheaper on earningsLower P/E, profitable companies only 398.5x -40.2x -27.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 30.8x — 24.6x FTRE
Faster revenue growthRevenue growth, trailing twelve months -1.2% +41.7% -2.6% GH
More profitableNet margin, trailing twelve months 1.0% -37.9% -2.6% CRL
Better return on capitalReturn on invested capital 0.0% — 0.8% FTRE
Less leveragedLower net debt / EBITDA 5.1x — 9.2x CRL
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +99.8% +61.2% +97.7% CRL
Better 5-year returnAnnualised price return, 5 years -2.6%/yr +7.9%/yr — GH
Less volatileAnnualised volatility, 1 year 47.6% 53.0% 67.9% CRL
Higher overall scoreMean of the five percentile scores vs peers 54/100 27/100 58/100 FTRE

Percentile Scorecard

CRLGHFTRE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCRLGHFTRE
Valuation 70 #4 of 11 15 #84 of 99 90 #2 of 11
Growth 10 #10 of 11 44 #50 of 89 90 #2 of 11
Profitability 70 #4 of 11 9 #84 of 92 50 #6 of 11
Financial Health 50 #7 of 13 54 #48 of 103 0 #13 of 13
Shareholder Returns 71 #3 of 8 13 #55 of 63 –
Overall 54 27 58
  • CRL ranked among 13 companies in Pharma Services
  • GH ranked among 103 companies in Healthcare Providers
  • FTRE ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCRLGHFTRESPY
1 month +12.0%-6.9%-5.3% -2.0%
3 months +20.7%-3.5%+16.0% -2.8%
6 months +124.1%+59.8%+47.9% +2.0%
Year to date +69.5%+48.5%+17.1% +10.6%
1 year +99.8%+61.2%+97.7% +12.2%
3 years +89.5%+519.4%-37.8% +68.1%
3 years, per year +23.8%+83.7%-14.7% +18.9%
5 years -12.4%+46.1%— +61.4%
5 years, per year -2.6%+7.9%— +10.1%
10 years +353.0%—— +248.5%
10 years, per year +16.3%—— +13.3%

Risk

MeasureCRLGHFTRESPY
Volatility, 1Y 47.6%53.0%67.9% 13.6%
Downside volatility, 1Y 44.7%50.7%64.3% 13.9%
Beta vs S&P 500, 1Y 1.271.321.68 1.00
Return / volatility, 1Y 2.101.151.44 0.90
Max drawdown, 5Y -74.7%-85.0%-89.9% -25.4%
From 52-week high -10.1%-19.0%-21.9% -3.2%
52-week high $375.83$187.22$25.88 $779.14
52-week low $149.93$78.60$8.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCRLGHFTRE
P/E now vs peer median 402.1xmedian 34.7x -42.0xmedian 22.4x -28.1xmedian 34.7x
P/S now vs peer median 4.1xmedian 2.5x 16.0xmedian 1.3x 0.7xmedian 2.5x
EV/EBITDA now vs peer median 41.5xmedian 29.1x -40.6xmedian 14.2x 30.5xmedian 29.1x
P/FCF now vs peer median 40.5xmedian 21.0x -88.0xmedian 19.0x 11.5xmedian 21.0x
P/B now vs peer median 5.0xmedian 1.6x -74.1xmedian 2.6x 3.7xmedian 1.6x
PEG now vs peer median -6.49median 1.98 -72.47median 0.84 0.46median 1.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCRLGHFTRE
Revenue $3.98B $1.28B $2.67B
Gross profit $1.33B $833.70M $533.40M
Operating income $158.98M -$504.04M $12.80M
Net income $39.65M -$485.07M -$68.70M
Free cash flow $399.63M -$232.15M $169.00M
R&D – $386.67M –
EPS (diluted) $0.83 $-3.61 $-0.68
Cash & equivalents $200.38M $1.03B $220.60M
Total debt $2.44B – $1.06B
Shares (diluted) 48.58M 134.42M 101.20M
Enterprise value $15.22B $15.12B $1.18B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCRLGHFTRE
P/E 402.1x -42.0x -28.1x
P/FCF 40.5x -88.0x 11.5x
P/Operating cash flow 26.0x -117.8x 9.7x
P/S 4.1x 16.0x 0.7x
P/B 5.0x -74.1x 3.7x
P/Tangible book 5.4x -67.9x -49.1x
EV/EBITDA 41.5x -40.6x 30.5x
EV/EBIT 115.9x -38.5x 218.2x
EV/Revenue 4.6x 15.2x 1.0x
EV/FCF 46.1x -83.6x 16.5x
EV/Operating cash flow 29.6x -111.9x 13.8x
PEG (3Y EPS CAGR) -6.49 -72.47 0.46

Growth

14 metrics
MetricCRLGHFTRE
Revenue growth (1Y) -1.2% 41.7% -2.6%
Revenue CAGR (3Y) -1.9% 33.6% 0.4%
Gross profit growth (1Y) 2.1% 44.9% 2.4%
Gross profit CAGR (3Y) -4.8% – -8.5%
Operating income growth (1Y) 12.8% -13.9% 101.5%
Operating income CAGR (3Y) -37.4% 0.6% -43.3%
Net income growth (1Y) 149.8% -21.6% 93.0%
Net income CAGR (3Y) -56.5% -3.9% -47.8%
EPS growth (1Y) 149.0% -12.9% 93.7%
EPS CAGR (3Y) -61.9% 0.6% -60.7%
Operating cash flow growth (1Y) -17.0% 22.2% 589.8%
Operating cash flow CAGR (3Y) -3.7% 19.9% 76.5%
Free cash flow growth (1Y) -26.5% 11.5% 347.8%
Free cash flow CAGR (3Y) 2.7% 13.9% 148.9%

Profitability

14 metrics
MetricCRLGHFTRE
Gross margin 33.3% 65.2% 20.0%
EBITDA margin 11.2% -37.4% 3.4%
Operating margin 4.0% -39.4% 0.5%
Pretax margin -2.5% -38.0% -2.0%
Net margin 1.0% -37.9% -2.6%
FCF margin 10.0% -18.2% 6.3%
Operating cash flow margin 15.7% -13.6% 7.6%
Return on equity 1.4% – -13.0%
Return on assets 0.6% -25.5% -2.5%
Return on invested capital 0.0% – 0.8%
Return on capital employed 2.5% -33.0% 0.7%
Asset turnover 0.5x 0.7x 1.0x
Cash conversion (OCF / net income) 15.7x 0.4x -2.9x
Stock comp / revenue 2.0% 16.5% 1.9%

Financial Health

11 metrics
MetricCRLGHFTRE
Debt / assets 32.8% – 38.9%
Debt / equity 0.8x – 2.0x
Net debt / EBITDA 5.1x – 9.2x
Debt / FCF 6.1x – 6.3x
Liabilities / assets 56.6% 114.6% 80.6%
Equity / assets 43.4% -14.6% 19.4%
Interest coverage 1.5x -96.6x –
Current ratio 1.4x 3.6x 1.0x
Quick ratio 0.9x 3.3x 0.9x
Cash ratio 0.2x 2.8x 0.2x
Altman Z-score 3.30 3.60 0.78

Shareholder Returns

7 metrics
MetricCRLGHFTRE
Dividend yield – – –
Net buyback yield 1.8% -2.0% –
Shareholder yield 1.8% -2.0% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCRLGHFTRE
Forward P/E 30.8xFY2026 – 24.6xFY2026
EPS, next fiscal year $10.99FY2026 $-3.46FY2026 $0.82FY2026
EPS growth, next FY +6.9%FY2026 – +90.7%FY2026
EPS growth, the year after +20.7% – +19.5%
Revenue, next fiscal year $3.85BFY2026 $1.43BFY2026 $2.79BFY2026
Revenue growth, next FY -4.2%FY2026 +45.5%FY2026 +2.5%FY2026
Revenue growth, the year after +1.2% +26.0% -3.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCRLGHFTRE
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 571 597 331
Change in shares held, QoQ -0.7% -2.5% -0.2%
Institutions buying 271 356 139
Institutions selling 204 180 108
Buyers to sellers 1.33 1.98 1.29

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CRLGHFTRE
CRL 1.00 0.41 0.64
GH 0.41 1.00 0.33
FTRE 0.64 0.33 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CRL, GH and FTRE?

Guardant Health (GH) is the largest by market capitalisation: Charles River Laboratories International (CRL) $16.01B, Guardant Health (GH) $19.50B, Fortrea Holdings (FTRE) $1.89B.

Which company is growing faster?

Guardant Health (GH) grew revenue fastest over the trailing twelve months: Charles River Laboratories International (CRL) -1.2%, Guardant Health (GH) +41.7%, Fortrea Holdings (FTRE) -2.6%.

Which company is more profitable?

Charles River Laboratories International (CRL) has the highest net margin (Charles River Laboratories International (CRL) 1.0%, Guardant Health (GH) -37.9%, Fortrea Holdings (FTRE) -2.6%). On return on invested capital, Fortrea Holdings (FTRE) leads (Charles River Laboratories International (CRL) 0.0%, Fortrea Holdings (FTRE) 0.8%).

Which stock has performed better?

Over the past year Charles River Laboratories International (CRL) returned the most: Charles River Laboratories International (CRL) +99.8%, Guardant Health (GH) +61.2%, Fortrea Holdings (FTRE) +97.7%. Over five years, Guardant Health (GH) compounded fastest (Charles River Laboratories International (CRL) -2.6%/yr, Guardant Health (GH) +7.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Charles River Laboratories International (CRL) has been the steadiest (Charles River Laboratories International (CRL) 47.6%, Guardant Health (GH) 53.0%, Fortrea Holdings (FTRE) 67.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CRL, GH and FTRE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Charles River Laboratories International (CRL) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.